Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on October 30, 2019, to report the entry into a Material Definitive Agreement. The company is listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics related to the transaction include:
- Shares Issued: 3,529,412 shares of common stock.
- Offering Price: $0.85 per share.
- Net Proceeds: Approximately $2.6 million (excluding the over-allotment option).
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 529,411 additional shares.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the execution of an Underwriting Agreement with Aegis Capital Corp. to conduct a public offering of common stock. Additionally, certain executive officers, directors, and 5% beneficial owners have agreed to a lock-up period, refraining from selling or transferring securities for 180 days starting November 4, 2019.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on operational outlook, or a discussion of risks and contingencies beyond the standard representations and warranties customary for underwriting agreements. The transaction relies on an effective registration statement on Form S-3 declared effective on October 10, 2017.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting all underwriting discounts and offering expenses.
- Confirm whether the underwriters exercised the 45-day over-allotment option to purchase the additional 529,411 shares.
- Review the final prospectus supplement filed on October 31, 2019, for updated use of proceeds and risk factors.
- Monitor the company's cash runway and burn rate to assess the impact of the $2.6 million infusion on operational sustainability.